News
Issued by Kahn Swick & Foti, not ImmunityBio, Inc.
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
May 21, 2026 · View original source (Newsfile)
It isn’t one of ImmunityBio, Inc.’s news releases, so 6ix doesn’t show it on ImmunityBio, Inc.’s page or send it as an alert.